Rhode Island House Bill H7020

Rhode Island 2022 Regular Session

• Introduced: 1/10/22
• Refer: 1/10/22

Caption

The Breast Cancer Act

Impact

The proposed legislation is designed to strengthen existing health care policies concerning breast cancer awareness and detection. It will particularly benefit women who are underinsured or uninsured by establishing a program that guarantees access to these critical screening services. By sponsoring screenings and follow-up diagnostics, this act aims to support individuals in navigating the alarming incidence of breast cancer, providing necessary preventive care that could result in early detection and treatment.

Summary

House Bill H7020, also known as 'The Breast Cancer Act', focuses on enhancing coverage for breast cancer screening procedures in the state. The bill mandates coverage for mammograms and digital breast tomosynthesis (dbt) screenings for all individual or group hospital and medical expense insurance policies. It requires that such coverage adhere to guidelines established by the American Cancer Society and allows for specific provisions for women at high risk of breast cancer, including those who have previously been treated for the disease. This aligns the health insurance landscape with contemporary medical recommendations.

Contention

Debate surrounding H7020 is expected to focus on the implications for insurance providers and the potential costs for both insurers and the state’s health budget. Critics might argue about the financial strain that mandated coverages could impose, while proponents will emphasize the necessity of ensuring that all women have the opportunity to receive potentially life-saving screenings. The amendment of existing laws to include newer technological advancements in breast cancer detection, like dbt, positions the state as a leader in cancer care, yet could spark discussions about balancing innovation with fiscal responsibility.